ES2554927T3 - Formulación que comprende un derivado de fenilaminopirimidina como agente activo - Google Patents

Formulación que comprende un derivado de fenilaminopirimidina como agente activo Download PDF

Info

Publication number
ES2554927T3
ES2554927T3 ES11764851.9T ES11764851T ES2554927T3 ES 2554927 T3 ES2554927 T3 ES 2554927T3 ES 11764851 T ES11764851 T ES 11764851T ES 2554927 T3 ES2554927 T3 ES 2554927T3
Authority
ES
Spain
Prior art keywords
weight
pharmaceutical composition
relation
total weight
nrc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11764851.9T
Other languages
English (en)
Spanish (es)
Inventor
Durga Maheswari Parvataneni
Siddhartha YEDLURI
Venkata Satyanarayana APPADWEDULA
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2554927(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Application granted granted Critical
Publication of ES2554927T3 publication Critical patent/ES2554927T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES11764851.9T 2011-03-07 2011-08-10 Formulación que comprende un derivado de fenilaminopirimidina como agente activo Active ES2554927T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201103860 2011-03-07
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
ES2554927T3 true ES2554927T3 (es) 2015-12-28

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11764851.9T Active ES2554927T3 (es) 2011-03-07 2011-08-10 Formulación que comprende un derivado de fenilaminopirimidina como agente activo

Country Status (33)

Country Link
US (1) US9895367B2 (enExample)
EP (1) EP2683381B1 (enExample)
JP (1) JP5788534B2 (enExample)
KR (1) KR101767296B1 (enExample)
CN (1) CN103561742B (enExample)
AP (1) AP4076A (enExample)
AU (1) AU2011361921B2 (enExample)
BR (1) BR112013022930A2 (enExample)
CA (1) CA2829015C (enExample)
CO (1) CO6811851A2 (enExample)
CY (1) CY1116968T1 (enExample)
DK (1) DK2683381T3 (enExample)
EA (1) EA024610B1 (enExample)
ES (1) ES2554927T3 (enExample)
GB (1) GB2488788B (enExample)
GE (1) GEP20156410B (enExample)
HR (1) HRP20151382T1 (enExample)
HU (1) HUE025562T2 (enExample)
IL (1) IL228218A (enExample)
MA (1) MA35088B1 (enExample)
MX (1) MX339130B (enExample)
MY (1) MY158693A (enExample)
NZ (1) NZ614903A (enExample)
PH (1) PH12013501844A1 (enExample)
PL (1) PL2683381T3 (enExample)
PT (1) PT2683381E (enExample)
RS (1) RS54420B1 (enExample)
SG (1) SG193349A1 (enExample)
SI (1) SI2683381T1 (enExample)
SM (1) SMT201500235B (enExample)
UA (1) UA111074C2 (enExample)
WO (1) WO2012120328A1 (enExample)
ZA (1) ZA201306643B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3389633T1 (sl) * 2015-12-18 2021-11-30 Natco Pharma Ltd Farmacevtski sestavki, ki vsebujejo derivat fenilaminopirimidina
WO2017115316A1 (en) * 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
PL3765024T3 (pl) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div>
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
CN1208047C (zh) * 1997-07-29 2005-06-29 法玛西雅厄普约翰美国公司 亲脂性化合物的自体乳化剂
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
BRPI0515081B8 (pt) * 2004-09-09 2021-05-25 Natco Pharma Ltd composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida
US20080207904A1 (en) * 2006-10-26 2008-08-28 Macdonald Peter Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
MX2009011479A (es) * 2007-04-30 2010-02-01 Intezyne Technologies Inc Micelas de copolimero de bloque hibrido con estereoquimica mezclada para encapsulacion de hidrofobos.
US8067422B2 (en) * 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
GEP20135882B (en) * 2008-03-04 2013-07-25 Natco Pharma Ltd Crystal form of phenylamino pyrimidine derivatives
CN102137858B (zh) * 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂

Also Published As

Publication number Publication date
WO2012120328A1 (en) 2012-09-13
CY1116968T1 (el) 2017-04-05
JP5788534B2 (ja) 2015-09-30
AP4076A (en) 2017-03-23
GB2488788B (en) 2013-07-10
SI2683381T1 (sl) 2016-01-29
UA111074C2 (uk) 2016-03-25
BR112013022930A2 (pt) 2016-12-06
EA024610B1 (ru) 2016-10-31
GB201103860D0 (en) 2011-04-20
EP2683381A1 (en) 2014-01-15
PT2683381E (pt) 2015-11-02
CN103561742B (zh) 2016-04-27
IL228218A (en) 2016-06-30
SG193349A1 (en) 2013-10-30
DK2683381T3 (en) 2015-12-21
CO6811851A2 (es) 2013-12-16
AU2011361921B2 (en) 2016-06-09
MA35088B1 (fr) 2014-05-02
PH12013501844A1 (en) 2015-10-23
ZA201306643B (en) 2014-11-26
JP2014507463A (ja) 2014-03-27
US9895367B2 (en) 2018-02-20
EA201391280A1 (ru) 2014-02-28
AP2013007128A0 (en) 2013-09-30
MY158693A (en) 2016-11-15
CA2829015A1 (en) 2012-09-13
AU2011361921A1 (en) 2013-09-26
NZ614903A (en) 2014-08-29
HRP20151382T1 (hr) 2016-02-12
SMT201500235B (it) 2015-10-30
RS54420B1 (sr) 2016-04-28
PL2683381T3 (pl) 2016-06-30
GEP20156410B (en) 2015-12-10
AU2011361921A2 (en) 2014-10-30
MX2013010160A (es) 2013-12-06
KR20140016926A (ko) 2014-02-10
US20130338180A1 (en) 2013-12-19
KR101767296B1 (ko) 2017-08-10
GB2488788A (en) 2012-09-12
CN103561742A (zh) 2014-02-05
EP2683381B1 (en) 2015-09-16
HUE025562T2 (en) 2016-03-29
CA2829015C (en) 2018-01-02
MX339130B (es) 2016-05-13

Similar Documents

Publication Publication Date Title
US9474727B2 (en) Pharmaceutical compositions of curcumin
ES2657813T3 (es) Composiciones farmacéuticas para calanolidas, sus derivados y análogos, y proceso para su producción
ES2748562T3 (es) Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma
CA2829015C (en) Formulation comprising phenylaminopyrimidine derivative as active agent
RU2009131749A (ru) Многофазные фармацевтические композиции плохо растворимых в воде лекарственных соединений для уменьшения вариабельности при приеме после еды/натощак и для улучшения пероральной биодоступности
JP6852204B2 (ja) 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
AU2015270187A1 (en) Oral pharmaceutical composition of isotretinoin
JP2017530149A (ja) 低用量経口イソトレチノイン医薬組成物
ES2643135T3 (es) Composiciones farmacéuticas que comprenden alisporivir
JP2017521470A (ja) イソトレチノインの経口医薬組成物
TW202320735A (zh) 卡博替尼的自微乳組合物
US20200345646A1 (en) Liquid filled formulations of pde5 inhibitors
ES2358205T3 (es) Composición farmacéutica para administración oral.
JP7149611B2 (ja) 薬物を保持した非水系組成物およびその製造方法
KR100986531B1 (ko) 액상의 아세클로페낙을 함유하는 캡슐제
JP2000355552A (ja) オキサトミド製剤